SCHEMBL20810039

SCHEMBL20810039

COc1cccc(-c2cc(COC(=O)c3cccnc3Cl)on2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.51
▸ MEN1 O00255 5/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ POLB P06746 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ RECQL P46063 1/20 0.51
▸ RXFP1 Q9HBX9 2/20 0.49
▸ L3MBTL1 Q9Y468 4/20 0.47
▸ TDP1 Q9NUW8 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ NPC1 O15118 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20810051 0.90 L3MBTL1 (0.56) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810022 0.87 MAPT (0.46) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20809988 0.87 POLB (0.60) KMT2AMEN1RAB9APOLBL3MBTL1
SCHEMBL20810040 0.84 POLB (0.51) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810213 0.83 RXFP1 (0.53) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810046 0.83 L3MBTL1 (0.61) KMT2AMEN1RAB9APOLBL3MBTL1
SCHEMBL20810043 0.83 L3MBTL1 (0.55) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810050 0.82 KMT2A (0.55) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810049 0.81 POLB (0.48) KMT2AMEN1RAB9APOLBLMNA
SCHEMBL20810047 0.81 POLB (0.51) KMT2AMEN1RAB9APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT KMT2A 3849/4885MEN1 1993/4885RAB9A 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback